CN112423774A - 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 - Google Patents

用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 Download PDF

Info

Publication number
CN112423774A
CN112423774A CN201980047677.1A CN201980047677A CN112423774A CN 112423774 A CN112423774 A CN 112423774A CN 201980047677 A CN201980047677 A CN 201980047677A CN 112423774 A CN112423774 A CN 112423774A
Authority
CN
China
Prior art keywords
disease
cpg
circulating
dementia
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980047677.1A
Other languages
English (en)
Chinese (zh)
Inventor
L·H·L·特兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN112423774A publication Critical patent/CN112423774A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980047677.1A 2018-05-15 2019-05-15 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法 Pending CN112423774A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862671485P 2018-05-15 2018-05-15
US201862671466P 2018-05-15 2018-05-15
US62/671,466 2018-05-15
US62/671,485 2018-05-15
US201862674855P 2018-05-22 2018-05-22
US62/674,855 2018-05-22
PCT/US2019/032403 WO2019222339A1 (en) 2018-05-15 2019-05-15 Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders

Publications (1)

Publication Number Publication Date
CN112423774A true CN112423774A (zh) 2021-02-26

Family

ID=68541027

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980047677.1A Pending CN112423774A (zh) 2018-05-15 2019-05-15 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法

Country Status (9)

Country Link
US (3) US11090303B2 (https=)
EP (1) EP3843768A4 (https=)
JP (2) JP7699378B2 (https=)
CN (1) CN112423774A (https=)
AU (1) AU2019271189A1 (https=)
BR (1) BR112020023252A2 (https=)
GB (1) GB202015788D0 (https=)
MA (1) MA53500A (https=)
WO (1) WO2019222339A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
CN119770491A (zh) * 2024-12-20 2025-04-08 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398792A1 (en) * 2018-05-15 2024-12-05 Lloyd Hung Loi Tran Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
EP3843768A4 (en) * 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS
GB2613460B (en) * 2020-04-20 2025-07-23 Lloyd Hung Loi Tran Pharmaceutical Compositions for use in methods for the prophylaxis or treatment of COVID such as COVID-19; and compound for use in the treatment of a
WO2022051631A1 (en) * 2020-09-03 2022-03-10 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
TW202245773A (zh) * 2021-02-12 2022-12-01 紐西蘭商紐藍製藥公司 普威二氏症候群之治療
KR20260049797A (ko) * 2023-07-12 2026-04-14 로이드 트란 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
WO2025088052A1 (en) * 2023-10-26 2025-05-01 Rousselot Bv Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis
WO2025160184A1 (en) * 2024-01-23 2025-07-31 Lloyd Tran Methods for the prophylaxis and treatment of obesity and related conditions and disorders
WO2025179250A1 (en) * 2024-02-25 2025-08-28 Lloyd Tran Methods for the prophylaxis and treatment of autism related disorders
WO2025198995A1 (en) * 2024-03-18 2025-09-25 Lloyd Tran Methods for the prophylaxis and treatment of stroke related disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US20030109531A1 (en) * 2001-11-13 2003-06-12 Tran Loi H Therapeutic agent composition and method of use
US20060258663A1 (en) * 2003-09-03 2006-11-16 Neuren Pharmaceuticals Limited Cyclic G-2AllylProline in treatment of Parkinson's disease
CN101466366A (zh) * 2006-06-15 2009-06-24 纽朗制药公司 用于治疗认知障碍的α-氨基酰胺衍生物
US20090232775A1 (en) * 2002-11-20 2009-09-17 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20110201614A1 (en) * 2003-09-03 2011-08-18 Michael John Bickerdike Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
US20150306171A1 (en) * 2001-11-13 2015-10-29 Lloyd Hung Loi Tran Therapeutic agent composition and method of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2670563B2 (ja) 1988-10-12 1997-10-29 富士通株式会社 半導体装置の製造方法
JP2757960B2 (ja) 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
SE8803847A0 (sv) 1988-10-27 1990-04-28 Kabigen Ab Neuromodulerande peptid
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5439930A (en) 1992-04-14 1995-08-08 Russian-American Institute For New Drug Development Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5942422A (en) 1996-11-14 1999-08-24 The Trustees Of Columbia University In The City Of New York Method for generating a directed, recombinant fusion nucleic acid
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
US6124361A (en) 1997-12-31 2000-09-26 Pfizer Inc Bicyclo[3.1.0]hexanes and related compounds
PT1064256E (pt) 1998-03-17 2004-10-29 Pfizer Prod Inc Biciclo[2.2.1] heptanos e compostos relacionados
US6258582B1 (en) 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
AU781044B2 (en) 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
US6689904B2 (en) 2001-06-29 2004-02-10 Wyeth Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
WO2015013397A2 (en) * 2013-07-25 2015-01-29 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
JP2021514303A (ja) * 2018-02-19 2021-06-10 ザ マテリアル ワークス，リミテッド 金属薄板デスケーラのための幅及び速度コントロールならびにそれを使用する方法
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US20030109531A1 (en) * 2001-11-13 2003-06-12 Tran Loi H Therapeutic agent composition and method of use
US20150306171A1 (en) * 2001-11-13 2015-10-29 Lloyd Hung Loi Tran Therapeutic agent composition and method of use
US20090232775A1 (en) * 2002-11-20 2009-09-17 Goran Bertilsson Compounds and methods for increasing neurogenesis
US20060258663A1 (en) * 2003-09-03 2006-11-16 Neuren Pharmaceuticals Limited Cyclic G-2AllylProline in treatment of Parkinson's disease
US20110201614A1 (en) * 2003-09-03 2011-08-18 Michael John Bickerdike Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
CN101466366A (zh) * 2006-06-15 2009-06-24 纽朗制药公司 用于治疗认知障碍的α-氨基酰胺衍生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114582507A (zh) * 2022-03-04 2022-06-03 青海省畜牧兽医科学院 基于地理探测器的泡型包虫病环境风险因子分析方法
CN119770491A (zh) * 2024-12-20 2025-04-08 北京大学 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用

Also Published As

Publication number Publication date
JP7699378B2 (ja) 2025-06-27
WO2019222339A1 (en) 2019-11-21
EP3843768A4 (en) 2022-11-23
US12070458B2 (en) 2024-08-27
BR112020023252A2 (pt) 2021-02-23
JP2021524864A (ja) 2021-09-16
EP3843768A1 (en) 2021-07-07
GB202015788D0 (en) 2020-11-18
US20200054629A1 (en) 2020-02-20
AU2019271189A1 (en) 2021-01-07
US11090303B2 (en) 2021-08-17
MA53500A (fr) 2021-08-18
US20220000866A1 (en) 2022-01-06
US20230381175A1 (en) 2023-11-30
JP2025084741A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
CN112423774A (zh) 用于治疗轻度认知障碍、抑郁和心理障碍的治疗剂组成及使用方法
US12150958B2 (en) Compositions and methods for treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and associated methods for preparing said compositions
WO2022194109A1 (zh) 一种治疗视神经疾病的复合物及其制备方法和用途
TW201134482A (en) Aptamers to β -NGF and their use in treating β -NGF mediated diseases and disorders
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
CN107266332A (zh) Ssao的取代的3‑卤代烯丙基胺抑制剂及其用途
TW201038544A (en) Anti-neurodegenerative diseases agents
JP2016539188A (ja) 新規カベオリンモジュレーターを使用する自己免疫および／または炎症疾患の治療
CN102625707A (zh) Hip/pap或其衍生物的新应用
CN116390723A (zh) 用于将生物素递送至线粒体的方法和组合物
JP2021527127A (ja) 中枢神経系内のグルコースレベルを増強する方法
CN106459016B (zh) 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药
JP2022552217A (ja) 脊髄損傷の治療のため及び／又は髄鞘再形成のためのペプチドの全身投与
CN102813914B (zh) 一种用于治疗或预防脑血管及相关疾病的药物组合物
US20240398792A1 (en) Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease
US20240374691A1 (en) Glp-1r agonists for use in a treatment of neurologial impairment associated with viral infection
CN121443298A (zh) 用于治疗持续性脑震荡后症状的苯加兰他敏
CN101658522A (zh) 他克林短链二聚体在制备治疗神经退行性疾病药物中的应用
WO2023068176A1 (ja) 神経細胞増殖促進剤及びその使用
CN121816183A (zh) 治疗轻度认知障碍的治疗剂组合物以及联合疗法的应用方法
Yin et al. TGF-β/RhoA/ROCK Signaling Activation Orchestrates Ciliary Body EMT and Fibrosis in Myopia
RU2744453C2 (ru) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
Yanamadala Peptide carriers to improve uptake and functionality and to cross BBB to arrest secondary injury post TBI
RU2362554C2 (ru) Регенерирующее противовоспалительное средство и способы лечения с помощью этого средства
WO2025179250A1 (en) Methods for the prophylaxis and treatment of autism related disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination